Bagsværd, Denmark, 04 November 2022 – Today, Novo Nordisk A/S has entered into an settlement to buy 4,207,500 B shares of DKK 0.20 at a price of DKK 3,582 million from Novo Holdings A/S. The transaction is a part of Novo Nordisk A/S’ 2022 share repurchase programme of as much as a complete of DKK 24 billion to be executed throughout a 12-month interval starting 2 February 2022. The transaction worth is DKK 851.26 per share and has been calculated because the three-day quantity weighted common market worth from 2 November 2022 to 4 November 2022 within the open window following the announcement of Novo Nordisk A/S’ quarterly monetary outcomes.
Prior to the sale of B shares, Novo Holdings A/S’ possession of Novo Nordisk A/S was 28.2% of the share capital and 77.0% of the votes. Following the transaction, Novo Holdings A/S owns 537,436,000 A shares of DKK 0.20 and 102,104,000 B shares of DKK 0.20, corresponding to twenty-eight.1% of the capital and 76.9% of the votes in Novo Nordisk A/S.
The transaction is consistent with the announcement on 2 November that Novo Holdings A/S intends to keep up its possession of Novo Nordisk A/S’ share capital round 28%.
With the transactions said above, Novo Nordisk A/S owns a complete of 27,443,142 B shares of DKK 0.20, akin to 1.2% of the share capital, as treasury shares. The complete variety of A and B shares within the firm is 2,280,000,000 of DKK 0.20 together with treasury shares.
About Novo Holdings A/S
Novo Holdings A/S is a non-public restricted legal responsibility firm wholly owned by the Novo Nordisk Foundation. It is the holding firm of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is chargeable for managing the Novo Nordisk Foundation’s belongings. Novo Holdings is acknowledged as a number one worldwide life science investor, with a give attention to creating long-term worth. As a life science investor, Novo Holdings offers seed and enterprise capital to development-stage corporations and takes vital possession positions in progress and well-established corporations. Novo Holdings additionally manages a broad portfolio of diversified monetary belongings. Further info: www.novoholdings.dk.
About Novo Nordisk A/S
Novo Nordisk is a number one international healthcare firm, based in 1923 and headquartered in Denmark. Our goal is to drive change to defeat diabetes and different severe persistent illnesses comparable to weight problems and uncommon blood and endocrine issues. We accomplish that by pioneering scientific breakthroughs, increasing entry to our medicines, and dealing to forestall and in the end remedy illness. Novo Nordisk employs about 53,000 individuals in 80 international locations and markets its merchandise in round 170 international locations. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For extra info, go to novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for additional info
Company announcement No 81 / 2022
